ArticleJHLT open2026
Left ventricular assist device infections: From epidemiology to treatment.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Enterococcal Infections in Left Ventricular Assist Device Recipients: Two Clinical Cases and Systematic Review.Pathogens (Basel, Switzerland) · 2026Pooled it
- The role of continuous in situ targeted antimicrobials in the successful treatment of extensively-drug resistantJHLT open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Infections are among the most frequent and severe complications in patients supported with left ventricular assist devices (LVADs), significantly affecting morbidity, mortality, and transplant candidacy. Driveline infections are the most common, but involvement of the pump or pocket is associated with more complex management and worse outcomes. Methods: We conducted a comprehensive narrative review of current literature on LVAD infections, including epidemiology, updated definitions, microbiology, diagnostic tools, and treatment strategies in both bridge-to-transplant and destination therapy patients. Results: Infection rates range from 19% to 39%, with Conclusions: Management of LVAD infections requires individualized, multidisciplinary strategies. Despite technological advances, prevention and early diagnosis remain critical. Further studies are needed to define best practices and reduce infection-related morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.